Welcome to our dedicated page for Orthofix Medical news (Ticker: $OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orthofix Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orthofix Medical's position in the market.
Orthofix Medical Inc. (NASDAQ:OFIX) reported strong first quarter 2024 results with net sales of $188.6 million, a 7.7% increase on a reported basis. The company saw growth across key segments, including Bone Growth Therapies, U.S. Spine Fixation, and Global Orthopedics. Despite a net loss of $36 million, the Non-GAAP Adjusted EBITDA increased to $7.7 million, showing a 220 basis point expansion. Orthofix raised its full-year net sales guidance to $790.0-$795.0 million, emphasizing continued growth and profitability.